Obesity drug developer Metsera said on Friday that it had accepted Pfizer's $10 billion acquisition offer, in what could ...

Medicare will start covering obesity drugs for the first time, which could open access to millions of seniors and spur more ...

Shares in Novo Nordisk fell as much as 3% on Friday after the Danish drugmaker and U.S. rival Eli Lilly agreed with the U.S.

U.S. President Donald Trump, Eli Lilly and Novo Nordisk unveiled a deal on Thursday to slash the prices of popular GLP-1 ...

Certain GLP-1 weight loss medications will be available for as little as $149 per month, a sharp drop from the current ...

Pfizer has won the bidding war against Novo Nordisk to acquire obesity-drug biotech Metsera. The pharma giant upped its offer ...

Pedersen and Maggie Fick COPENHAGEN (Reuters) -Shares in Novo Nordisk and Eli Lilly slipped on Friday after both agreed with ...

Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.

A fierce bidding war could be costly for Novo Nordisk. The stock price for Danish drugmaker Novo Nordisk (NYSE: NVO) is down more than 8% since last Friday's close. What's going on with this former ...

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...

There's a lot of buzz about the popular GLP-1 weight loss drugs after President Donald Trump announced this week a deal with ...